pmlive.com
Cure8 news brief
Eli Lilly's Omvoh granted FDA approval to treat Crohn's disease in adults - PMLiVE
Medications
Mirikizumab
IL-23 inhibitor
Abdominal Pain
Urgency
FDA Approval
Adult patients
Patients On Biologics
Why This Matters
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3 clinical trial evidence showing improved remission and intestinal healing versus placebo.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, patients who have failed or intolerant to steroids/immunomodulators/biologics, clinicians treating IBD, and researchers following IL-23 targeted therapies.
Study Snapshot
Story typeCompany update
Evidence typeFDA Approval
Source depthFull source text
What To Know
The FDA decision expands an existing IBD indication for mirikizumab into Crohn’s disease. The VIVID-1 trial met both primary endpoints, with higher rates of clinical remission and endoscopic healing at one year versus placebo, and VIVID-2 open-label data show sustained responses with longer treatment.
The article notes the drug was studied in patients who had inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators or biologics.
Regulatory context: The EMA’s human medicines committee recently recommended mirikizumab for Crohn’s disease and the European Commission will consider that recommendation; the US approval follows the FDA review. Next steps for patients: This is a regulatory approval announcement, not treatment guidance.
Patients should discuss options with their clinicians to understand whether mirikizumab is appropriate for their individual history and prior treatments.
Keep In Mind
This article reports a regulatory approval based on the VIVID-1 and VIVID-2 studies; it does not provide full prescribing details, long-term safety data, or comparative effectiveness versus other available therapies. Treatment decisions should be based on detailed trial data and clinician judgment.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationpmlive.com
Indexed viaGoogle News
Source typeCompany update
PublishedJan 16, 2025, 12:36 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly secures FDA approval for Omvoh to treat Crohn's disease
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...